{"id":1014012,"date":"2026-10-27T09:38:14","date_gmt":"2026-10-27T13:38:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/"},"modified":"2026-10-27T09:38:14","modified_gmt":"2026-10-27T13:38:14","slug":"vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/","title":{"rendered":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems"},"content":{"rendered":"
\n

\n Phase 2a pilot study aims to inform the design and conduct of future\u00a0<\/em>
\n
\n Phase 3\u00a0research\u00a0in this population<\/em>\n <\/p>\n

\n Cadisegliatin is a potential first-in-class oral therapy being\u00a0evaluated\u00a0as an adjunct to insulin for the treatment of T1D <\/em>\n <\/p>\n

HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.<\/a> (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin\u2019s potential in this growing segment of the T1D population and to inform additional clinical studies.<\/p>\n

Automated insulin delivery (AID) systems, also called closed-loop or artificial pancreas systems, combine a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to adjust insulin delivery automatically. HCL systems, the most common type of AID, automate basal insulin adjustments but still require the user to, for example, manage insulin dosing for meals or periods of exercise.<\/p>\n

\u201cAlthough HCL systems have\u00a0improved the lives of people living with T1D,\u00a0the\u00a0risk and associated fear\u00a0of hypoglycemia remain a significant burden on their day-to-day\u00a0lives,\u201d said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. \u201cAs we advance our\u00a0cadisegliatin\u00a0program, this study\u00a0seeks\u00a0to deepen our understanding of how\u00a0cadisegliatin may\u00a0help\u00a0improve glycemic control and reduce\u00a0the burden of hypoglycemia for\u00a0people\u00a0who use HCL insulin delivery systems.\u201d\u00a0\u00a0<\/p>\n

An estimated 2.1 million people in the United States live with T1D,i<\/sup> with up to 40% of people with T1D now using AID systems.ii<\/sup>,<\/sup>iii,<\/sup>iv<\/sup> Yet over 40% of people with T1D who use AID systems still do not achieve the target A1C of less than 7.0%.v<\/sup><\/p>\n

Earlier this month, vTv Therapeutics announced the completion of enrollment<\/a> in its Phase 3 CATT1 study of cadisegliatin for T1D. Because the Phase 3 study only enrolled participants using insulin pens or insulin pumps in an open-loop fashion, this Phase 2a pilot study will provide complementary insights into cadisegliatin\u2019s metabolic effects in individuals using AID systems and inform larger future clinical studies.<\/p>\n

\n About the\u00a0Phase\u00a02a\u00a0Hybrid CATT1\u00a0Pilot\u00a0Study\u00a0<\/strong>
\n
The\u00a0Phase 2a\u00a0C<\/strong>adisegliatin\u00a0as\u00a0A<\/strong>djunctive\u00a0T<\/strong>herapy to Insulin in Participants with\u00a0T<\/strong>1D Who Are Using HCL Systems\u00a0(Hybrid CATT1) study is a double-blind, randomized, placebo-controlled, two-way\u00a0crossover study assessing\u00a0cadisegliatin\u00a0as an adjunctive treatment\u00a0to\u00a0insulin in adults with T1D using\u00a0HCL\u00a0insulin delivery systems.<\/p>\n

The multicenter study is expected to enroll approximately 40 adults with T1D who have used an HCL system for at least three months before screening. The primary objective is to evaluate the effect of cadisegliatin on continuous glucose monitoring (CGM)-based measures of glycemic control, including Time in Range (TIR), following six weeks of treatment. The study also includes standardized mixed-meal tolerance tests to evaluate the effects of cadisegliatin on postprandial glucose excursions.<\/p>\n

For\u00a0more information on the\u00a0Phase 2a\u00a0Hybrid CATT1\u00a0Pilot Study, visit https:\/\/clinicaltrials.gov\/study\/NCT07616206<\/a>.\u00a0<\/p>\n

\n About\u00a0Cadisegliatin<\/strong>\u00a0
Cadisegliatin\u00a0(TTP399)\u00a0is a novel, oral, liver-selective small molecule glucokinase activator being investigated in the U.S. as a potential first-in-class adjunctive treatment for T1D. In nonclinical studies,\u00a0cadisegliatin\u00a0acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether\u00a0cadisegliatin\u00a0can improve glycemic control through hepatic glucose uptake and glycogen storage.\u00a0Cadisegliatin\u00a0has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).\u00a0<\/p>\n

Cadisegliatin\u00a0is under investigation, and its\u00a0safety\u00a0and efficacy have not been\u00a0established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.\u00a0<\/p>\n

\n About<\/strong>\u00a0vTv<\/strong>\u00a0Therapeutics<\/strong>\u00a0
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv\u2019s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com<\/a> or follow the company on LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>\u00a0
This release\u00a0contains\u00a0forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of\u00a0cadisegliatin\u00a0to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other\u00a0important factors\u00a0that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.\u00a0Important factors\u00a0that could cause our results to vary from expectations include those described under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K,\u00a0subsequent\u00a0Quarterly Reports on Form 10-Q and our other filings with the\u00a0SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We\u00a0anticipate\u00a0that\u00a0subsequent\u00a0events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions,\u00a0mergers, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.\u00a0<\/p>\n

\n Investor Contact<\/strong>
\n
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com<\/a><\/p>\n

\n i<\/sup> Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2026 update (2023 estimates)
ii<\/sup> Tandem Diabetes Care, Inc. Investor Presentation,<\/a> August 2026, slide 4. Available at investor.tandemdiabetes.com.
iii<\/sup> Beta Bionics, Inc. Investor Presentation<\/a>, September 2026, slide 6. Available at investors.betabionics.com
iv <\/sup>Insulet Corporation. Investor Presentation, September 2026<\/a>, slide 10. Available at investors.insulet.com
v <\/sup>Wu Z, Rabasa-Lhoret R, et al. Despite lower haemoglobin A1c with second-generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes. Diabetes Obes Metab<\/em>. 2026;28(2):1150-1159. doi:10.1111\/dom.70299<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Phase 2a pilot study aims to inform the design and conduct of future\u00a0 Phase 3\u00a0research\u00a0in this population Cadisegliatin is a potential first-in-class oral therapy being\u00a0evaluated\u00a0as an adjunct to insulin for the treatment of T1D HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin\u2019s potential in this growing segment of the T1D population and to inform additional clinical studies. … <\/p>\n

Continue reading “vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014012","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nvTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Phase 2a pilot study aims to inform the design and conduct of future\u00a0 Phase 3\u00a0research\u00a0in this population Cadisegliatin is a potential first-in-class oral therapy being\u00a0evaluated\u00a0as an adjunct to insulin for the treatment of T1D HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin\u2019s potential in this growing segment of the T1D population and to inform additional clinical studies. … Continue reading "vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T13:38:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems\",\"datePublished\":\"2026-10-27T13:38:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/\"},\"wordCount\":1183,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/\",\"name\":\"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=\",\"datePublished\":\"2026-10-27T13:38:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/","og_locale":"en_US","og_type":"article","og_title":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk","og_description":"Phase 2a pilot study aims to inform the design and conduct of future\u00a0 Phase 3\u00a0research\u00a0in this population Cadisegliatin is a potential first-in-class oral therapy being\u00a0evaluated\u00a0as an adjunct to insulin for the treatment of T1D HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin\u2019s potential in this growing segment of the T1D population and to inform additional clinical studies. … Continue reading \"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T13:38:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems","datePublished":"2026-10-27T13:38:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/"},"wordCount":1183,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/","name":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=","datePublished":"2026-10-27T13:38:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMxNSM3OTE2MjIwIzIwMTk3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-first-participant-randomized-in-phase-2a-pilot-study-evaluating-cadisegliatin-in-individuals-with-type-1-diabetes-t1d-using\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"vTv Therapeutics Announces First\u00a0Participant\u00a0Randomized in Phase 2a\u00a0Pilot\u00a0Study Evaluating\u00a0Cadisegliatin\u00a0in\u00a0Individuals\u00a0with Type 1 Diabetes\u00a0(T1D) Using\u00a0Hybrid Closed-Loop\u00a0(HCL)\u00a0Insulin\u00a0Delivery Systems"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014012"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014012\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}